This study is for patients having breast-conserving surgery, a procedure where only the cancerous part of the breast is removed. It focuses on a drug called SRG-514, which is given during the surgery. The study is in its first phase, meaning it's the first time this drug is being tested in humans. Researchers want to find the best dose to use in future studies. They will increase the dose slowly to see how much patients can safely handle. About 12-18 patients will be part of this study. **Eligibility:** Patients must be 18 or older, weigh more than 50 kg (about 110 pounds), and have certain types of breast cancer. They must also be planning to have breast-conserving surgery. **Exclusions:** Patients can't participate if they're allergic to ketorolac (a pain reliever) or need other treatments during surgery like drains or reconstruction. **Key Points:** - The study will check for any side effects 14 days after the drug is given. - Patients get the drug during their surgery. - Participants are closely monitored for safety and any side effects. This study may be a good option for those meeting the eligibility criteria who are interested in helping advance breast cancer treatments.